The 30-second summary
- Tirzepatide hits two receptors (GLP-1 and GIP); semaglutide hits one (GLP-1). That extra target is the whole story behind the efficiency gap.
- In the only head-to-head trial, SURMOUNT-5, tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide over 72 weeks. Meta-analyses in 2026 confirm a real but smaller everyday gap.
- On paper tirzepatide loses more weight, but semaglutide owns the long-term outcome data for heart and kidney protection. The right molecule is the one you can tolerate, access, and sustain.
Tirzepatide vs semaglutide: what each molecule actually is
This is a molecule question, not a brand question. Semaglutide is the drug inside Ozempic and Wegovy. Tirzepatide is the drug inside Mounjaro and Zepbound. If you want the brand-by-brand version of this comparison, read Mounjaro vs Wegovy. Here we stay at the molecule level, because that is what the research compares.
Semaglutide is a GLP-1 receptor agonist. It mimics one gut hormone, glucagon-like peptide-1, which slows how fast your stomach empties, steadies blood sugar, and quiets the appetite signalling many women describe as food noise.
Tirzepatide is a dual agonist. It mimics GLP-1 and a second hormone, glucose-dependent insulinotropic polypeptide, or GIP. The second receptor appears to add to appetite suppression and metabolic effect. Think of semaglutide as one strong lever and tirzepatide as two levers pulled together. Both are once-weekly injections you can give in the abdomen, thigh, or upper arm.
The head-to-head evidence
For years the comparison was indirect, trial against trial. That changed with SURMOUNT-5, the first randomised head-to-head study, published in 2025. It enrolled 751 adults with obesity or overweight plus a weight-related condition, but without type 2 diabetes, and ran for 72 weeks at the maximum tolerated dose of each drug.
The result was clear. Tirzepatide produced an average 20.2% reduction in body weight versus 13.7% for semaglutide. Nearly a third of the tirzepatide group lost at least 25% of their starting weight, compared with about one in six on semaglutide. Tirzepatide won the primary endpoint and every key secondary endpoint.
A wave of 2026 systematic reviews and meta-analyses tells the same direction with a calmer margin. Pooled randomised data put tirzepatide roughly 4.6 percentage points ahead. A 6-month real-world cohort in ordinary clinics, where doses are lower and people miss shots, found a narrower gap: about 11.2% versus 8.8%. The lesson worth keeping: trial numbers are the ceiling, not the forecast for your kitchen and your calendar.
Side effects: more alike than different
Both molecules are gastrointestinal drugs first. The most common complaints on either are nausea, constipation, and that early queasy week. Steady tracks 14 of these symptoms precisely because they are the reason most women stop, not the scale.
In SURMOUNT-5 the side-effect profiles looked broadly similar, mostly mild-to-moderate gut symptoms that eased with slow titration. Because tirzepatide pushes harder on appetite, some women find the early weeks more intense and need a gentler ramp. Whichever you take, the same playbook applies: titrate slowly, eat enough protein, hydrate, and do not rush the dose. See managing day-three nausea and staying hydrated on GLP-1.
One quiet risk affects both: rapid loss strips muscle alongside fat. Older semaglutide data showed lean mass can account for a meaningful share of total loss, and tirzepatide is no different in principle. Muscle is what keeps you steady, strong, and metabolically healthy. Read protecting muscle on GLP-1 and strength training while losing weight.
Heart and kidney outcomes: the case for semaglutide's track record
Weight loss is one number. What a drug does to your heart and kidneys over years is a different, more important one, and here the order flips.
Semaglutide has the deeper outcome evidence. The SELECT trial, 17,604 people with obesity and existing cardiovascular disease but no diabetes, found semaglutide cut major adverse cardiovascular events, meaning cardiovascular death, heart attack, and stroke, by 20% versus placebo over nearly four years. The FLOW trial then showed a 24% reduction in major kidney disease events in people with type 2 diabetes and chronic kidney disease. That is hard, long-term protection, not a surrogate.
Tirzepatide's outcome story is younger but encouraging. SURPASS-CVOT, published in late 2025, compared tirzepatide against dulaglutide (an established GLP-1 with proven heart benefit) in over 13,000 people with type 2 diabetes. Tirzepatide was non-inferior, with roughly an 8% relative reduction in cardiac events and a 16% reduction in all-cause death versus its comparator. What is still missing is a placebo-controlled cardiovascular trial in obesity of the size and length of SELECT. The data favour tirzepatide on weight and semaglutide on years of proven protection. For more, see GLP-1 and heart health and GLP-1 and kidney health.
Cost and access reality
The molecule you can actually get and afford every month beats the one that wins on paper. Access shifts constantly: insurance coverage, prior authorisation, supply, and which brand is approved for diabetes versus weight management all differ by drug and by country. Compounded versions add another layer of uncertainty and quality questions, covered in the truth about compounded GLP-1. The practical move is to treat access as a real decision factor, not an afterthought, and to bring it to your prescriber rather than chasing the highest trial number.
The real decision criteria for a woman
Skip the leaderboard. Four questions decide this better than any percentage:
- Tolerate. Which one lets you function at work and at home? The drug you can stay on at an effective dose wins.
- Access. Which one can you reliably get and afford, month after month, without rationing?
- Sustain. Which fits your life for the long run? Weight regain after stopping is common with both, so this is a years-long choice. See what happens when you stop.
- What you do alongside. Protein, strength work, and sleep shape your result more than the molecule does. The drug quiets food noise; the habits decide what you keep.
Bring this comparison to your prescriber. A woman with established heart or kidney concerns has a strong reason to value semaglutide's outcome record; a woman whose main barrier is appetite and who tolerates titration well may do better on tirzepatide. There is no universal winner, only your best fit.
What Steady does with this
- Steady tracks 14 GLP-1 symptoms over time, so you and your prescriber can see whether nausea, constipation, or fatigue is settling or worsening, on either molecule.
- Steady protects what matters under the scale: it nudges protein and strength habits so more of what you lose is fat, not the muscle that keeps you steady.
- Steady turns a month into one clean page for your appointment, including dose, symptoms, weight trend, and cycle, so the tirzepatide-versus-semaglutide conversation is grounded in your data, not guesswork.
Read next: Mounjaro vs Wegovy: the brand-level guide, Protecting muscle on GLP-1, GLP-1 and heart health
Sources
- Aronne LJ, et al. Tirzepatide vs Semaglutide for Obesity (SURMOUNT-5), 72-week phase 3b results, 20.2% vs 13.7%. New England Journal of Medicine, 2025. SURMOUNT-5 head-to-head trial coverage
- Head-to-head comparison of tirzepatide and semaglutide for weight loss: a systematic review and meta-analysis. ScienceDirect, February 2026. Meta-analysis (PMC mirror)
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT), 20% MACE reduction. New England Journal of Medicine, 2023. SELECT trial summary, American College of Cardiology
- Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW), 24% reduction in major kidney events. New England Journal of Medicine, 2024. FLOW trial in NEJM
- SURPASS-CVOT: tirzepatide non-inferior to dulaglutide on MACE. New England Journal of Medicine, December 2025. SURPASS-CVOT coverage, tctmd
Medical disclaimer: Articles in the Steady research hub are educational, not medical advice. They cannot account for your personal history, medications, or risks. Always discuss treatment choices, including whether tirzepatide or semaglutide is right for you, with a qualified clinician. See our full medical disclaimer.